DOPAMINE AGONIST

Question 1

MOA?

Answer 1

directly stimulate postsynaptic DA receptor

Question 2

used as?

Answer 2

mono therapy or as adjunct

Question 3

non-ergoline equals?

Answer 3

pramipexole (PO)
ropinirole (PO)
rotigotine (transdermal)
apomorphine (SQ)

Question 4

non-ergoline has long or short duration of action? useful in patients with what phenomenon? preferred in what patient pop?

Answer 4

long duration of action (8-24 hrs)

on-off phenom

younger patients to preserve L-dopa

Question 5

non-ergoline is ineffective in what type of patients?

Answer 5

with no therapeutic responses to levodopa

Question 6

this is a type of non-ergoline that is SQ only?

why is test dose imp?

Answer 6

apomorphine, used for temp rescue of severe rigidity or inability to move (off episodes)

necessary to ensure tolerability

Question 7

ergoline equals? AEs?

Answer 7

bromocriptine

pulmonary fibrosis
raynauds phenom
CV valvular fibrosis

Question 8

all DA drugs leads to?

Answer 8

impulsivity, greatest being with DA agonist

Question 9

ropinirole, pramipexole, rotigotine are dopamine agonists that are also the same agents for?

Answer 9

restless leg syndrome

Question 10

preferred in what age groups?

Answer 10

younger patients

Question 11

in advanced disease, DA can be added to levodoa for mainly?

Answer 11

minimizing response fluctuations

Question 12

non ergoline AEs?

Answer 12

sleep attacks
impulsivity
hyperprolactinemia
confusion
orthostatic hypotension

Question 13

provides temporary rescur of severe rigidity or inability to move

MOA:stimulates postsynaptic D2 type receptors within caudate putamen

test dose necessary

titrate to effective dose

Answer 13

apomorphine

Question 14

new drug

MOA: adenosine (A2A) receptor antagonist involved in motor control

adverse effects: dyskinesia, insomnia, hallucinations, dizziness, contsipation

A2A receptors are widespread (spleen, thymus, leukocytes)

Answer 14

Istradefylline